Management of Decompensated HCV Cirrhotic Patients

NCT03547895 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

80

Enrollment

OTHER_GOV

Sponsor class

Conditions

Decompensated Cirrhosis

Interventions

DRUG: Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)
DRUG: vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion

Sponsor

Zagazig University